Tag: Purdue

Categories
Health

Richard Sackler Says Household and Purdue Bear No Accountability for Opioid Disaster

Richard Sackler Says Family and Purdue Bear No Responsibility for Opioid Crisis

Until the third hour of the testimony before the Federal Insolvency Court by Dr. Richard Sackler, a former president and co-chair of the board of directors of Purdue Pharma, the prescription opioid maker founded by members of the Sackler family, asked a lawyer a chain of questions:

“Do you have any responsibility for the opioid crisis in the United States?”

“No,” replied Dr. Sackler, 76, weak.

“Does the Sackler family have any responsibility for the opioid crisis in the United States?”

Again “No”.

And finally:

“Is Purdue Pharma responsible for the opioid crisis in the US?”

More consequently: “No.”

Dr. Sackler, perhaps the most famous of the Sacklers billionaire, who for nearly 20 years was the family member who played the primary role in launching his signature prescription pain reliever, OxyContin, seldom videoconferenced Wednesday before a judge holding the confirmatory hearing for a plan who would reorganize Purdue and resolve all lawsuits against the company and family members over their role in the opioid epidemic.

It is believed to be the first time Dr. Sackler publicly answered questions about the family’s opioid business. Similar to an expanded testimony presented to Kentucky state attorneys in 2015, Dr. Sackler presented his legal department with a testimony that was largely littered with faint or absent memories, brief statements, and distractions.

His voice was often barely audible, he apologized for his laryngitis, and occasionally appeared to be fiddling with the technology that posed annoying volume challenges and opening documents emailed to him when he testified.

While he did not provide any new insights into what is already known about the roles of Sackler’s family members in the company, his looks were remarkable for what he refused to admit.

Dr. Sackler had been called on for questioning by attorneys for states opposed to the plan, in part because they believe the Sacklers will receive extensive legal protection in return for paying $ 4.5 billion.

In a biting back and forth, Dr. Sackler, he doesn’t know how many Americans died from OxyContin. “In your role as chairman or president of an opioid company, you did not find it necessary to determine how many people died as a result of this product?” Asked Brian Edmunds, an assistant attorney general from Maryland.

“To the best of my knowledge, data is not available,” replied Dr. Sackler.

Dr. Sackler – who trained as an internist but embarked on a career as a pharmaceutical manager for the Stamford, Connecticut-based company originally owned in part by his father, Dr. Raymond Sackler – is known for throwing himself into Purdue’s operation. In a testimony on Wednesday, Dr. Sackler that he and a Purdue sales representative drove calls to doctors to increase sales. The sales force eventually focused on doctors, who tended to prescribe higher doses, said Dr. Sackler. He acknowledged that higher-dose opioids could result in higher profits for the company.

During his tenure, Purdue twice confessed to federal criminal charges related to the marketing and sale of OxyContin and settled with Kentucky.

Lawsuits against the Sacklers and Purdue received numerous emails from Dr. Sackler cited, including one from 2001 cited in a Massachusetts lawsuit. “We must take every possible means against the perpetrators,” he wrote. “You are the culprit and the problem. They are ruthless criminals. “

In 2019, the Sackler family contributed $ 75 million to Oklahoma as part of a larger settlement between the state and Purdue. In this case, as in a civil law settlement between the federal government and the Sacklers in 2020, family members did not admit any wrongdoing.

“I cannot enumerate all the settlements,” said Dr. Sackler. “There were many settlements, both private and public.”

The Maryland, Washington State, and Connecticut lawyers apparently attempted to extract such shards to put them back together, arguing that the Sacklers were deeply involved in Purdue’s business.

The settlement agreement negotiated by Purdue and the Sacklers with states, tribes, local governments and other plaintiffs would not only settle the lawsuits, but would also give the company immunity from future civil claims, a condition customarily accorded to companies emerging from bankruptcy restructuring .

But this plan would also give similar protection to the Sacklers who did not file for bankruptcy. The question of such comprehensive legal protection for the Sacklers has driven many of the remaining objections to the plan.

If Judge Robert Drain’s plan is upheld as expected by the U.S. Southern New York Bankruptcy Court at White Plains, the Sacklers will not be pursued by those who contradict the plan, let alone future litigants for Purdue – related issues.

And that ban isn’t just limited to opioid-related cases. Benjamin Higgins, an attorney for the U.S. Trustee Program, a Department of Justice unit that oversees bankruptcy cases, noted that, for example, Purdue had in recent years introduced a long-acting stimulant to treat symptoms of attention deficit / hyperactivity disorder and that if any lawsuits occurred in the In connection with this drug would be considered, the Sacklers would also be vaccinated against it.

Dr. Sackler said he was not very familiar with the details of the extensive litigation clears that are at the core of Purdue’s bankruptcy plan.

“It’s an extremely dense document,” said Dr. Sackler. “I read a page or two and realized that it would take me a lot of time.”

In accordance with the complex structure of the Sackler payments to a national opioid trust, the contributions are partly financed by the prospective sale of the various pharmaceutical companies of the family members worldwide.

“Will you personally be contributing your own assets to the settlement payments in the next nine or ten years?” Sackler was asked.

“I don’t know,” he replied. “I don’t think that’s decided yet.”

Categories
Health

Purdue Pharma’s Collectors Overwhelmingly Endorse Chapter Plan

Purdue Pharma’s Creditors Overwhelmingly Endorse Bankruptcy Plan

A large majority of Purdue Pharma’s more than 120,000 creditors have voted to approve the company’s bankruptcy plan, a major step toward the eventual release of more than $ 4.5 billion to help cover the cost of the opioid epidemic and its settlement Thousands of lawsuits to be paid against the company and its owners, members of the billionaire Sackler family.

A preliminary poll by cities, states, tribes, insurers, families and caregivers of babies born with withdrawal symptoms after exposure to opioids in utero showed 95 percent are in favor of the plan, the company said.

According to the plan, the Sacklers would give up control of Purdue. The restructured company was to be resurrected under a new name and run by an independently appointed board of directors. Profits the sale of its signature prescription pain reliever, OxyContin, and addiction quenching drugs would go to creditor trusts that would fund addiction prevention and treatment programs.

The Sacklers, who did not file for personal bankruptcy, would pay at least $ 4.5 billion of their personal wealth over nine years (in addition to $ 225 million from a separate civil settlement with the Justice Department).

Neither the company nor the Sacklers would admit any wrongdoing in connection with these lawsuits.

In the past two decades, more than 500,000 people have died from prescription and illegal opioid overdoses in the United States, including a record number in 2020. Purdue, which is widely believed to have helped ignite the problem by causing it Has downplayed OxyContin’s addictive potential and aggressively marketed the drug with misleading campaigns pleaded guilty to two separate Justice Department inquiries.

For the complex plan to take effect, Judge Robert Drain must be signed by the US Bankruptcy Court for the southern borough of New York, a move long awaited and now made even more likely by the wholehearted result of the creditors’ vote. Purdue said it would release the final voting results on August 2nd, a week before a court hearing at which final objections will be raised, but the company does not expect those results to change materially. The judge is expected to rule shortly thereafter.

Although a handful of states, including the Justice Department, have objected to the plan, these efforts do not appear to cause the process to fail. Earlier this month, attorneys general of 15 states, including Massachusetts and New York, were among the most vocal objection, said they had negotiated new terms that made the plan more palatable and now supportive of the plan.

Among the new elements that reached the states and Purdue during the mediation was an agreement by the company to release more than 30 million documents to a public repository, including private communications with attorneys. These documents are expected to reveal the full history of the Company and Sacklers involvement in the sale of OxyContin.

Long known for their philanthropy in the arts, the Sacklers would give up future naming rights to any institutions they donate to until their contributions to the opioid agreement are paid in full.

For almost two years, the opposition states argued that they should be able to reach straight into the pockets of individual sacklers because they were not filing for bankruptcy protection themselves. However, under the terms of the Purdue Plan, the Sacklers and their company are exempt from any civil liability.

Some congressmen have passed legislation to fill a loophole in bankruptcy law. It would allow states, and possibly individuals, to sue for bankruptcy third-party business owners who, like the Sacklers themselves, have not filed for bankruptcy. But by the time the bill is passed, the Purdue plan and the status of the Sacklers will almost certainly be cleared up.

Categories
Health

15 States Attain a Deal With Purdue Pharma Over Opioids

15 States Reach a Deal With Purdue Pharma Over Opioids

At a press conference Thursday to announce the settlement, the Massachusetts, New York and Minnesota attorneys general pointedly noted that they had asked the Sacklers for years to admit guilt and apologize, but family members refused.

Government lawyers said that instead of spending years looking for more money to meet urgent needs created by the opioid epidemic, they agreed to step back in order to free funds faster.

New York Democrat Rep. Carolyn B. Maloney and California Democrat Mark DeSaulnier introduced a law they call the Sackler Act that would allow states to prosecute company owners in bankruptcy proceedings that the attorneys general are tracking down strongly support own statements. But even if Congress passed such a law, the attorneys general added, the Sacklers and Purdue would almost certainly have closed the case long ago and would have escaped the scope of the bill.

As such, Purdue will cease to exist as such and re-emerge as a new company that would manufacture limited quantities of OxyContin and overdose reversal drugs, according to the overall bankruptcy filing. It would be overseen by an appointed board of directors. The profits would feed payments to funds for distant plaintiffs that would primarily support drug treatment and prevention programs.

Lawyers involved in the negotiations underlined the importance of the public document archive, which can hardly be surpassed in its breadth and depth. Although Purdue has already produced 13 million documents during the litigation, it has now added 20 million more. The size of this one company’s documents rivals that uncovered by the entire tobacco industry, a coveted consequence of the Big Tobacco litigation some 20 years ago.

The Purdue documents will contain statements, emails, and letters that go back two decades. They are expected to reveal detailed details of Purdue’s behind-the-scenes contacts with federal investigators and Food and Drug Administration officials as the company fended off tougher penalties for promoting turbo sales that touted OxyContin as effective and non-addictive. Experts assume that the considerations and mandates of Dr. Richard Sackler, a former President and CEO of Purdue.

In Thursday’s briefing, Maura Healey, the Massachusetts attorney general who was the first to suing Sacklers, said the document pool served as a promise to the families of opioid victims. “It will tell the whole story, all of the conversations, all of the discussions, all of the planning, all of the ways they make money and evade accountability and regulation,” she said.

Categories
Health

Decide Clears Purdue Pharma’s Restructuring Plan for Vote by Hundreds of Claimants

Judge Clears Purdue Pharma’s Restructuring Plan for Vote by Thousands of Claimants

“It’s not unprecedented, but it’s highly controversial” for a bankrupt company’s owners to be released from future litigation as part of a settlement, said Adam J. Levitin, a law professor specializing in bankruptcy at Georgetown University Law Center. “It’s not even clear that the bankruptcy court has the jurisdiction to do this,” as the Sacklers are not parties to the bankruptcy themselves.

Judge Drain has long urged the negotiators to work quickly, because no money can flow to the claimants until the bankruptcy case is concluded.

According to the plan, the reconstituted, as-yet unnamed company would fund about a half-dozen trusts, including separate ones for tribes, adults and children. Proceeds from the sales of the nonprofit’s overdose-reversing medications as well as from moderate quantities of OxyContin would continue to be pumped into these trusts.

But more than 100,000 individual claimants, including relatives of people who died from prescription overdoses, would receive relatively paltry compensation, ranging roughly from $3,000 to $48,000 apiece — before lawyers’ fees and costs are deducted.

Indeed, more than a half-billion dollars overall will go toward fees and costs accrued by plaintiffs’ public and private lawyers.

The oversight of the new trusts will also be expensive. The trust distribution is incredibly complex, said Lindsey Simon, an assistant professor at the University of Georgia School of Law, who has closely followed the case. “From my perspective, the biggest question is how much money will get eaten up in the administration of all those trusts,” she said.

Scott Bickford, a lawyer who represents individuals, families and babies who showed symptoms of withdrawal from drugs they were exposed to in utero, noted that the current proposal did dedicate $60 million for programs to assist these children and a fund to compensate them, an improvement from earlier versions.

Categories
Health

Purdue Pharma Provides Plan to Finish Sackler Management and Mounting Lawsuits

Purdue Pharma Offers Plan to End Sackler Control and Mounting Lawsuits

In a message marking the beginning of the end of the most notorious prescription opioid maker in the country, Purdue Pharma unveiled its bankruptcy restructuring plan just before midnight on Monday. The blueprint requires members of the billionaire Sackler family to give up control of the company and transform it into a new business whose revenues are solely aimed at alleviating the addiction epidemic that caused its signature pain reliever, OxyContin.

The 300-page plan is the company’s formal offer to end thousands of lawsuits and includes the Sacklers pledge to pay $ 4.275 billion out of their personal assets – an additional $ 1.3 billion than their original offer – to reimburse states, communities, tribes and other plaintiffs for the costs associated with the epidemic.

If the plan is approved by a majority of the company’s creditors and Judge Robert D. Drain of Federal Bankruptcy Court in White Plains, NY, payments will flow into three buckets: one to compensate individual plaintiffs, such as families whose relatives have overdosed , or legal guardians of infants with newborn abstinence syndrome as well as hospitals and insurers; another for tribes; and the third – and largest – for state and local governments devastated by the cost of a drug epidemic that only worsened during the Covid-19 pandemic.

“With drug overdose still at record levels, it is time to use Purdue’s fortune to help tackle the crisis,” said Steve Miller, chairman of the Purdue board of directors, in a statement. “We are confident that this plan will achieve this important goal. ”

It remains to be seen whether the plan will be adopted. Since the company filed for bankruptcy in 2019, 24 states and the District of Columbia have denounced it, arguing that the lawsuit would preclude their ability to take legal action directly against individual Sackler family members who they consider to be inadequate contributions.

Although some details of the settlement terms are still being worked out, Purdue officials said the Sacklers would not be exempt from criminal investigations that could be launched by a handful of states for violating consumer protection laws. However, the plan exempts them from further civil litigation.

The new application, filed minutes before a court-set deadline, marks a milestone in Purdue’s long, troubled history as the maker and marketer of OxyContin, the prescription pain reliever that has become addicting hundreds of thousands of people. Federal and state agencies spent years trying to curb Purdue’s marketing tactics. In 2007, the Justice Department reached an agreement with Purdue and top executives on $ 634.5 million to resolve criminal charges related to its marketing practices.

As of 2015, when the opioid epidemic hit the country, the lawsuit engulfed cities, counties, states, tribes, families, hospitals and insurers, drug distributors, pharmacies and manufacturers, including Purdue boss. The cases almost consistently claim that OxyContin helped lay the foundation for the prescription and illicit drug addiction epidemic that killed more than 400,000 people over 20 years.

To halt the growing civil lawsuit that cost Purdue $ 2 million a week in legal costs, the company filed for bankruptcy protection in 2019.

The legal dispute before a federal court against other companies continues.

The biggest difference between Purdue’s earlier proposals and this latest plan is that the Sacklers increased their payments by $ 1.3 billion and extended their payment schedule by an additional two years (from seven to nine).

Another notable change concerns control of the new company. The original 2019 proposal called for it to be monitored by state-appointed officials. The restructuring plan now describes it as a private company run by independent managers selected by the states and local governments that sued Purdue. The largest groups of applicants – tribes and the government – own the company and would ensure that the proceeds are used solely for crisis management programs.

The company’s managers could sell to private owners by 2024, but those owners would also be bound by the same rules of conduct and income directions.

As it worked its way through the bankruptcy process, Purdue pleaded guilty in November of fraud against health officials and violating anti-kickback laws.

Individual members of the Sackler family agreed to pay the federal government civil fines of $ 225 million, but said in a statement that they “acted ethically and lawfully.” Although the Sacklers were not charged, the Justice Department reserves the right to file criminal charges later.

A key goal of the new Purdue plan is to install guard rails to ensure that settlement money is used to alleviate the epidemic, rather than being paid out more generally to cover budget constraints. Such payouts were a major criticism of the 1998 settlement that ended widespread legal disputes against the large tobacco companies that opioid disputes are sometimes compared to.

During the bankruptcy negotiations, pushed forward by the creditors, the company suggested in its plan that the payouts comply with the latest public health principles signed by at least two dozen major medical, drug policy, and academic institutions, and attention to drug prevention, youth education, and race set up justice and transparency.

Tens of thousands of parties vote on the plan. Confirmation hearings will follow and completion is expected in a few months. Since bankruptcy proceedings began 18 months ago, leaders of a large community bloc have signaled their support, as have 24 states.

Lloyd B. Miller, who represents numerous tribes including the Navajo Nation, said his customers were on board.

“It is critical that more funds go to the treatment of opioids in tribal communities, all the more given the extraordinary devastation tribes have suffered during the Covid pandemic,” he said.

But since 2019, when Purdue filed for bankruptcy, 24 other states – some controlled by Democrats, others by Republicans – and the District of Columbia have declined to take the move, finding that Purdue has continued to benefit from its OxyContin sales.

Maura Healey, the Massachusetts attorney general who was the first to sued individual members of the Sackler family, alleged that Sackler payments under this scheme would come from their investment returns rather than capital.

“The Sacklers became billionaires by causing national tragedy,” Ms. Healey said in a statement. “They shouldn’t be allowed to get away with paying a fraction of their investment returns over the next nine years and walking away richer than they are today.”

Opposing state attorneys general said the plan, while an improvement on previous proposals, still found it disappointing for several reasons. Among them, the plan should be amended to “achieve a speedy and orderly liquidation of the company that does not involve unduly states and other creditors”.

Two branches of the Sackler family – heirs to two brothers who founded the company – said: “Today is an important step in helping addicts and we hope that this proposed resolution signals the beginning of a far-reaching development. Make an effort to provide help where it is needed. “

The oldest brother, Dr. Arthur Sackler, sold his shares before OxyContin was launched, and his relatives are not part of the litigation.

A forensic review of the Sacklers’ finances commissioned by Purdue as part of bankruptcy investigations found that the family made more than $ 10 billion from the company from 2008 to 2017. Family lawyers said the full amount was illiquid: more than half went into taxes and investments in companies sold under the bankruptcy agreement.

Although states and other creditor blocs have protested vigorously against elements of the plan for the last 18 months, many factors seem to favor the likelihood of approval: the length of the litigation, the exorbitant costs for all parties, the urgency of the worsening opioid crisis, and the general depletion of public health resources due to the coronavirus pandemic.

The new company would continue to sell OxyContin, a pain reliever that is still approved by the Food and Drug Administration in limited circumstances. But it would diversify its products to include generics and a drug used to treat attention-deficit hyperactivity disorder, as well as new drugs to reverse overdose and treat addiction to be marketed as a public health initiative on a nonprofit basis.